● AI Equity Research · Healthcare

Kyverna Therapeutics, Inc. (KYTX)

AI stock analysis · Biotechnology · Last analyzed Aug 18, 2026

Compass Score

3.0/5

Call

Hold

Price

$8.95

AI Target

$30.40 +239.7%

AI Analyst Summary

Kyverna Therapeutics is a clinical-stage autoimmune cell therapy company whose bull thesis centers on its KYV-101 CAR-T program targeting refractory autoimmune diseases — a high-unmet-need category drawing intense investor and clinical interest. The analyst community is unanimously bullish, with all 6 covering analysts rating the stock Buy and a consensus price target implying over 239% upside from current levels. The primary risk is binary: as a pre-revenue biotech, KYTX's valuation depends entirely on clinical trial outcomes, and any safety or efficacy setback could be devastating to the share price.

Catalysts

KYV-101 clinical readouts in refractory systemic lupus erythematosus (SLE) and other autoimmune indications expected in upcoming quarters, which could serve as major de-risking events
Potential expansion of KYV-101 into additional autoimmune indications (e.g., myasthenia gravis, multiple sclerosis), broadening the addressable market and supporting re-rating
Possible partnership, licensing, or collaboration deal with a larger biopharma player, given the high strategic value of validated CAR-T autoimmune assets

Risks

Binary clinical risk: a safety signal or efficacy miss in any KYV-101 pivotal or key cohort readout could erase the majority of market cap, as there is no revenue base to cushion the blow
Cash runway and dilution risk: as a pre-revenue company with a negative forward P/E, continued operations depend on capital raises that may dilute existing shareholders significantly
Competitive pressure from well-capitalized rivals (e.g., Bristol-Myers Squibb's liso-cel program in autoimmune, Cartesian Therapeutics) that could erode KYV-101's first-mover advantage if competitors achieve earlier or superior clinical results

Fundamentals

Pe N/A (loss-making) · 1.0/5

No trailing P/E available; forward P/E is deeply negative at -2.9x, reflecting a pre-revenue clinical-stage biotech with no current earnings. Valuation is not applicable on traditional P/E metrics.

Peg N/A · 3.0/5

PEG ratio is unavailable for this clinical-stage company with no positive earnings. Scored neutrally per guidelines, as no growth denominator exists to calculate a meaningful ratio.

Analyst Rating Strong Buy consensus (1.3) · 5.0/5

Consensus rating of 1.3 on the inverted scale maps to the highest conviction tier. All 6 covering analysts rate the stock Buy, with zero Hold or Sell ratings — an exceptionally clean bullish sweep.

Earnings Trend N/A (pre-revenue clinical stage) · 3.0/5

No earnings or revenue growth data is available, as KYTX is a clinical-stage biotech. Scored neutrally; pipeline progression milestones rather than financial trends are the key value drivers at this stage.

Price Target Beat 4 of 4 quarters beat · 5.0/5

EPS beats in all 4 of the last 4 quarters reported. While EPS beats for a loss-making biotech largely reflect cost discipline and burn-rate management, a perfect beat rate signals strong operational execution relative to analyst models.

Management Strong execution signals · 4.0/5

Perfect 4-of-4 EPS beat rate indicates disciplined cash management and credible guidance. Unanimous analyst Buy coverage further reflects market confidence in management's ability to advance the pipeline and allocate capital effectively. Capped at 4 given limited operating history.

● See the full picture

Get today's top-scored picks, ranked for you.

Compass screens thousands of stocks every morning and hands you a short list of high-conviction picks — scored, explained, and re-ranked to your risk profile.

Start free for 3 days →

No credit card. Then $9/month. Cancel anytime.

How Compass scores stocks

Compass pre-filters thousands of U.S. equities by fundamentals, then an AI analyst scores each finalist 1–5 across six measures — spanning valuation, growth, analyst sentiment, and management quality — into one composite score, refreshed every market morning. Browse all covered stocks →

Not financial advice. Compass is an analytical tool, not a registered investment adviser or broker-dealer. Scores and recommendations are generated by AI, may be inaccurate or out of date, and are not investment, financial, legal, or tax advice. Investing involves risk, including loss of principal. Do your own research and consult a licensed financial professional. About Compass.